MAY 06, 2019 7:17 AM PDT

New insights on childhood cancer

Malignant rhabdoid tumor (MRT) is one of the worst cancer diagnoses a child can receive. While it is uncommon (or perhaps because it is), there are no standard effective treatments for MRT and most children will survive under a year.

MRT is so aggressive because it involves the loss of an anti-cancer protein called SNF5. The inactivation of SNF5 means that tumors are not suppressed; at the same time, the lost SNF5 also enables a pro-cancer protein called MYC to accelerate cancerous growth. Understanding this relationship has guided new research from Vanderbilt University, as scientists believe that targeting MYC in MRT patients might provide an effective treatment option.

"One of the difficulties in treating a cancer like MRT is that it's driven by the loss of a particular protein from the tumor cell," said William Tansey, PhD, Ingram Professor of Cancer Research and Professor of Cell and Developmental Biology. "Showing that MYC is activated by SNF5 loss identifies a target you can conceivably go after in these cancers," he said.

MRT cancer is one of the most aggressive pediatric cancers. Photo: Pixabay

MYC refers to a group of three related proteins that work as transcriptional regulators, meaning they control the expression of many genes linked to cell growth, proliferation, metabolism and genomic instability. In people with cancer, these proteins are expressed too much, which result in malignant tumors and cancerous growth. MYC overexpression leads to 100,000 cancer deaths annually in the United States.

Tansey and his colleagues are hoping that this new understanding of the connection between SNF5 and MYC proteins will promote future research in the field. As reported by Science Daily, the team of researchers utilized biochemical and genomic approaches to show that “SNF5 selectively inhibited binding of MYC to DNA, something that is required for its tumorigenic function. Accordingly, the reintroduction of SNF5 into MRT cells also displaced MYC from chromatin (the complex of DNA, RNA and protein that form chromosomes), inhibiting pro-cancerous gene expression programs.”

The research was published recently in the journal Nature Communications.

Sources: Nature Communications, Science Daily

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
SEP 16, 2020
Cancer
I'm addicted to the sun, are you?
SEP 16, 2020
I'm addicted to the sun, are you?
New research published in the Journal of Investigative Dermatology reports evidence that some people are geneticall ...
OCT 01, 2020
Cancer
Understanding in vivo Metabolomics: C13 Isotope Studies
OCT 01, 2020
Understanding in vivo Metabolomics: C13 Isotope Studies
One key to understanding cancer metabolomics lies in the ability to accurately replicate the natural environment of the ...
OCT 12, 2020
Cancer
Targeting Energy Production in Cells to Fight Leukemia
OCT 12, 2020
Targeting Energy Production in Cells to Fight Leukemia
Much like how a car needs gasoline to run, cells also need a fuel source. Most human cells in the body use oxidative pho ...
OCT 18, 2020
Cancer
Virus-mimicking drug attacks melanoma tumors
OCT 18, 2020
Virus-mimicking drug attacks melanoma tumors
Research published recently in the journal Science Translational Medicine from scientists at the UCLA Jonsson Compr ...
NOV 23, 2020
Cancer
Platelets May Protect Cancer Against PD-1 Therapies
NOV 23, 2020
Platelets May Protect Cancer Against PD-1 Therapies
One of cancer’s greatest tools is its ability to manipulate the immune system. Many cancer therapies have arisen t ...
NOV 25, 2020
Cancer
Using RNA to Diagnose HPV Associated Cancer
NOV 25, 2020
Using RNA to Diagnose HPV Associated Cancer
Diagnostic tools are critical to modern medicine. They might be less exciting than a good therapy or drug, but doctors a ...
Loading Comments...